Article

Case report: Intermediate uveitis caused by black ink tattoo

Author(s):

Jonathan D. Shader, DO, CPA, presents a case study involving an uncommon cause of posterior-intermediate uveitis: the black ink used to create a tattoo.

Intermediate uveitis caused by a black ink tattoo



Jonathan D. Shader, DO, CPA
, a resident at Western University of Health Science, College of Osteopathic Medicine, of the Pacific Northwest, Lebanon, OR, presented an uncommon cause of posterior-intermediate uveitis: the black ink used to create a tattoo.

A 39-year-old woman presented with bilateral ocular irritation, pain, photophobia, bilateral 1+ cells in the anterior chamber and vitreous, and puff ball at the ora, Shader described.

While the laboratory and imaging findings for uveitis were negative, this acute type of intermittent uveitis seemed to be associated with “swelling and induration of the patient’s black ink tattoos,” he pointed out.

Interestingly, this problem was not associated with tattoos created using other colors on the patient’s body.

When the black ink tattoo was made, no swelling or induration occurred at that time.

Treatment with oral prednisone resolved the symptoms, but they recurred with a steroid taper.

Adalimumab (Humira, Abbvie Inc.) successfully managed this case, Dr. Shader reported.

In commenting on the rarity of this reaction to black tattoo ink, he said that only a few such case series and reports of black ink tattoo associated uveitis have been reported.

“It is a condition with simultaneous inflammation of the eyes and skin, it is a bilateral, chronic, non-caseating granulomatous inflammation in individuals with extensive areas of tattooing that consist entirely of black ink,” he commented.

When a biopsy of the tattoos was performed, “a sarcoid-like reaction with granulomas that contained blank ink” was seen. Immunosuppression treatment and biologics are successful therapies in such cases.

This case was presented by Shader at the American Society of Cataract and Refractive Surgery as a poster from July 23-27, 2021.

He has no financial interest in this subject matter.


See more ASCRS coverage here

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
© 2025 MJH Life Sciences

All rights reserved.